Testing effectiveness (Phase 2)Active Not RecruitingNCT03838159What this trial is testingNADIM II: Neo-Adjuvant ImmunotherapyWho this might be right forNon Small Cell Lung Cancer Fundación GECP 90
Not applicableUnknownNCT02904850What this trial is testingValidation of a Kinetic Model of ErlotinibWho this might be right forLung Cancer University Hospital, Strasbourg, France 50
Not applicableStudy completedNCT02080650What this trial is testingCharacterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)Who this might be right forProstate CancerRenal Cell CarcinomaBladder Cancer+5 more Duke University 62
Large-scale testing (Phase 3)Active Not RecruitingNCT05132075What this trial is testingStudy of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer Novartis Pharmaceuticals 95
Testing effectiveness (Phase 2)UnknownNCT01170923What this trial is testingFDG-PET Scan Response Guided Chemotherapy Strategy for Advanced Non-small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Asan Medical Center 100
Early research (Phase 1)Ended earlyNCT01891669What this trial is testingPF-06263507 In Patients With Advanced Solid TumorsWho this might be right forNeoplasmsCarcinoma, Non Small Cell LungBreast Neoplasms+1 more Pfizer 26
Large-scale testing (Phase 3)Study completedNCT00003869What this trial is testingCarboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung CancerWho this might be right forStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer National Cancer Institute (NCI) 186
Large-scale testing (Phase 3)Study completedNCT01652469What this trial is testingTesting of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.Who this might be right forCarcinoma, Non-Small-Cell Lung ETOP IBCSG Partners Foundation 81
Testing effectiveness (Phase 2)Study completedNCT03535740What this trial is testingBrigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibWho this might be right forALK-positive Advanced NSCLC Ariad Pharmaceuticals 103
Very early researchStudy completedNCT04049474What this trial is testingBronchoscopic Cryo-Immunotherapy of Lung CancerWho this might be right forAdvanced Non-small Cell Lung Cancer NYU Langone Health 21
Large-scale testing (Phase 3)Looking for participantsNCT07185997What this trial is testingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsWho this might be right forNon-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung Cancer+3 more ArriVent BioPharma, Inc.
Early research (Phase 1)Active Not RecruitingNCT05068102What this trial is testingTest How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabWho this might be right forCarcinoma, Squamous Cell of Head and Neck (HNSCC)MelanomaNon-small Cell Lung Cancer (NSCLC) Boehringer Ingelheim 14
Testing effectiveness (Phase 2)Study completedNCT02417701What this trial is testingSapanisertib in Treating Patients With Stage IV or Recurrent Lung CancerWho this might be right forRecurrent Lung Squamous Cell CarcinomaStage IV Lung Squamous Cell Carcinoma AJCC v7 National Cancer Institute (NCI) 34
Early research (Phase 1)Study completedNCT05226728What this trial is testingPharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung CancerWho this might be right forNon-small Cell Lung Cancer Sun Yat-sen University 33
Large-scale testing (Phase 3)Active Not RecruitingNCT06396065What this trial is testingPhase III Study of AK112 for NSCLC PatientsWho this might be right forNon-Squamous Non-small Cell Lung Cancer Summit Therapeutics 420
Testing effectiveness (Phase 2)Ended earlyNCT00549328What this trial is testingMonotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung CancerWho this might be right forLung Cancer, Non-Small Cell GlaxoSmithKline 14
Testing effectiveness (Phase 2)Looking for participantsNCT06363734What this trial is testingOsimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II TrialWho this might be right forNon-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more Tianjin Medical University Cancer Institute and Hospital 32
Testing effectiveness (Phase 2)UnknownNCT04524299What this trial is testingStudy of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLCWho this might be right forNon-small Cell Lung Cancer Sun Yat-sen University 160
Testing effectiveness (Phase 2)UnknownNCT06182800What this trial is testingAdebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line ImmunotherapyWho this might be right forNon-small Cell Lung Cancer The First Affiliated Hospital of Xinxiang Medical College 35
Testing effectiveness (Phase 2)Study completedNCT05253807What this trial is testingStudy to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR AlterationWho this might be right forNon-Small Cell Lung Cancer (NSCLC) Incyte Corporation 8